Clinical evidence has established a strong link between lipoprotein(a) [Lp(a)] and the development and progression of atherosclerotic cardiovascular disease (ASCVD). Despite guidelines endorsing universal one-time testing for Lp(a), screening remains underutilized in clinical practice, and serves as a barrier for identifying at-risk patients who may benefit from emerging treatment options. Tune in to hear an expert panel of cardiologists discuss the critical relationship between Lp(a) and cardiovascular disease, and explore the latest strategies and emerging therapies for managing at-risk patients. Responding to real-world insights from a national survey of cardiologists, expert faculty will share practical strategies for overcoming barriers to integrating Lp(a) screening into comprehensive cardiovascular management plans. Don’t miss this opportunity to gain firsthand access to a point-of-care resource to support Lp(a) screening and risk assessment in your own practice.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/navigating-cardiovascular-risk-critical-role-lipoproteina-screening-treatment
- Start Date: 2024-10-14 05:00:00
- End Date: 2024-10-14 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 79750.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all